Loading...
Loading...
INZY| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 24.9M |
| Operating I/L | -24.9M |
| Other Income/Expense | 0.3M |
| Interest Income | 1.8M |
| Pretax | -24.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -24.6M |
Inozyme Pharma, Inc. is a rare disease biopharmaceutical company focused on developing therapeutics for abnormal mineralization affecting vasculature, soft tissue, and skeleton diseases. Its lead product candidate, INZ-701, is a soluble, recombinant protein designed to address rare genetic diseases such as ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. The company generates revenue through the development and potential commercialization of these therapeutic products, leveraging a license agreement with Yale University for specified therapeutic and prophylactic products.
